Zensar Technologies Employee Stock Options
Zensar Technologies allotted 31,440 equity shares to employees on exercise of ESOPs. Paid-up share capital rose to ₹45.55 crore across 22.78 crore shares.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
49 announcements
Zensar Technologies allotted 31,440 equity shares to employees on exercise of ESOPs. Paid-up share capital rose to ₹45.55 crore across 22.78 crore shares.
Zensar Technologies Ltd disclosed an employee's market sale of 20,000 equity shares on 02-11-2026, reducing holding from 41,977 to 21,977 shares. Value stated is Rs.1.09 Crore.
Zensar Technologies disclosed equity share sales by two employees totaling Rs. 0.75 Crore. Nimesh Khemka and Rajiv Mundhra executed market sales on November 2, 2026.
Zensar delivered secular revenue growth and margin expansion despite macro headwinds, pivotting heavily toward AI-native service delivery.
Zensar Technologies reported 4.1% sequential constant currency revenue growth to $166.2M for Q2FY27, with EBITDA margin at 15.8%. The release is a press release accompanying the quarterly results presentation.
Zensar's board approved merging its wholly owned subsidiary M3bi India into the parent. No consideration or share issuance is involved, and NCLT sanction is pending.
Zensar Technologies Ltd reported revenue from operations of ₹1,585 Cr (+11.5% YoY) and net profit of ₹190.2 Cr (+4.4% YoY) for Q2 FY27.
Zensar Technologies has been assigned an overall ESG rating of 76 in the 'Leader' category by NSE Sustainability Ratings and Analytics Limited.
Zensar Technologies submitted its Regulation 74(5) compliance certificate for the quarter ended September 30, 2026, confirming RTA dematerialization records were furnished to depositories.
Zensar Technologies allotted 162,619 equity shares upon the exercise of ESOPs by employees. This allotment increases the company's issued and subscribed share capital.
Zensar Technologies has scheduled a board meeting for October 28, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.
ICRA Limited has reaffirmed the credit rating of Zensar Technologies for its long-term and short-term fund/non-fund based bank facilities, totaling ₹191 Crore.
Designated person Vijayasimha Alilughatta acquired 8,983 shares of Zensar Technologies through an ESOP exercise. The transaction is valued at ₹0.43 Crore.
Zensar Technologies has allotted 25,691 equity shares to employees following the exercise of their vested ESOPs.
Zensar Technologies Ltd has filed its quarterly shareholding pattern for the period ended December 31, 2025, in compliance with regulatory requirements.
Zensar Technologies announced the completed merger of its US subsidiaries M3BI LLC and Bridgeview Life Sciences LLC into Zensar Technologies Inc. The mergers become effective September 1, 2026.
Zensar Technologies Limited has received an independent ESG score of 74 from Crisil ESG Ratings & Analytics Limited, categorizing the company under 'Leadership' for FY2026.
Zensar whitepaper outlining South Africa's financial services trends for 2026, focusing on payments-led commerce, AI adoption, and regulatory shifts.
Shareholders approved resolutions at Zensar Technologies' AGM, including a Rs. 750 Crore related party transaction with its South African subsidiary.
Zensar Technologies Limited concluded its 63rd Annual General Meeting on July 30, 2026. The meeting covered financial statements, dividend declaration, and related party transaction approvals.
Zensar Technologies has received in-principle board approval to merge its US-based step-down subsidiaries, Bridgeview Life Sciences LLC and M3BI LLC, into Zensar Technologies Inc.
Zensar Technologies reported Q1FY27 consolidated revenue of $159.5 million, reflecting 1.1% sequential constant-currency growth. The update highlights ongoing AI-led business transformation and strategic operational performance.
Zensar Technologies Ltd reported revenue from operations of ₹1,508 Cr (+8.9% YoY) and net profit of ₹183.8 Cr (+1.0% YoY) for Q1 FY27.
Zensar Technologies has filed a revised Integrated Annual Report for FY 2025-26 to correct an issue with the RPG Group logo in the document.
Zensar Technologies Limited has scheduled a board meeting on July 29, 2026, to consider and approve the unaudited standalone and consolidated financial results for Q1 FY2026-27.
Zensar Technologies has granted 6,28,502 stock options to eligible employees under the 'ESOP 2025' scheme. These options have an exercise price of ₹2 per option.
Zensar Technologies will hold its AGM on July 30, 2026, to approve FY26 financials and declare a final dividend of ₹12.60/share. It also seeks approval for ₹750 Cr related-party transactions with its South Africa subsidiary.
Zensar Technologies filed its BRSR for FY2025-26, detailing operations and subsidiaries. The report includes employee data and CSR metrics but no financial results or corporate action.
Zensar Technologies filed its Integrated Annual Report for FY2025-26. The report covers corporate overview, strategy, governance, and financial statements for shareholder review.
Zensar Technologies has issued a notice for its 63rd AGM on July 30, 2026. The agenda includes adopting financial statements and declaring a final dividend of INR 12.60 per share.